Update Breast Cancer 2021 Part 2-Advanced Stages, Long-Term Consequences and Biomarkers

被引：4

作者：

Ditsch, Nina ^{[1
]}

Stickeler, Elmar ^{[2
]}

Behrens, Annika ^{[3
]}

Belleville, Erik ^{[4
]}

Fasching, Peter A. ^{[3
]}

Fehm, Tanja N. ^{[5
]}

Hartkopf, Andreas D. ^{[6
]}

Jackisch, Christian ^{[7
]}

Janni, Wolfgang ^{[8
]}

Kolberg-Liedtke, Cornelia ^{[9
]}

Kolberg, Hans-Christian ^{[10
]}

Lueftner, Diana ^{[11
]}

Lux, Michael P. ^{[12
]}

Mueller, Volkmar ^{[13
]}

Schneeweiss, Andreas ^{[14
,15
]}

Schuetz, Florian ^{[16
]}

Schulmeyer, Carla E. ^{[3
]}

Tesch, Hans ^{[17
]}

Thomssen, Christoph ^{[18
]}

Uleer, Christoph ^{[19
]}

Untch, Michael ^{[20
]}

Welslau, Manfred ^{[21
]}

Woeckel, Achim ^{[22
]}

Wurmthaler, Lena A. ^{[3
]}

Wuerstlein, Rachel ^{[23
,24
]}

Thill, Marc ^{[25
]}

Aktas, Bahriye ^{[26
]}

机构：

[1] Univ Hosp Augsburg, Dept Gynecol & Obstet, Augsburg, Germany

[2] RWTH Univ Hosp Aachen, Dept Gynecol & Obstet, Aachen, Germany

[3] Friedrich Alexander Univ Erlangen Nuremberg, Comprehens Canc Ctr Erlangen EMN, Erlangen Univ Hosp, Dept Gynecol & Obstet, Univ Str 21-23, D-91054 Erlangen, Germany

[4] ClinSol GmbH & Co KG, Wurzburg, Germany

[5] Univ Hosp Dusseldorf, Dept Gynecol & Obstet, Dusseldorf, Germany

[6] Univ Tubingen, Dept Obstet & Gynecol, Tubingen, Germany

[7] Sana Klinikum Offenbach, Dept Obstet & Gynecol, Offenbach, Germany

[8] Ulm Univ Hosp, Dept Gynecol & Obstet, Ulm, Germany

[9] Univ Hosp Essen, Dept Gynecol & Obstet, Essen, Germany

[10] Marienhosp Bottrop, Dept Gynecol & Obstet, Bottrop, Germany

[11] Univ Med Berlin, Charite Univ Hosp, Dept Hematol Oncol & Tumour Immunol, Berlin, Germany

[12] St Vincenz Krankenhaus GmbH, St Josefs Krankenhaus, Frauenklin St Louise, Klin Gynakol & Geburtshilfe, Paderborn, Germany

[13] Hamburg Eppendorf Univ, Med Ctr, Dept Gynecol, Hamburg, Germany

[14] Heidelberg Univ Hosp, Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[15] German Canc Res Ctr, Heidelberg, Germany

[16] Diakonissen Stiftungs Krankenhaus Speyer, Gynakol & Geburtshilfe, Speyer, Germany

[17] Bethanien Hosp Frankfurt, Frankfurt, Germany

[18] Martin Luther Univ Halle Wittenberg, Dept Gynaecol, Halle, Saale, Germany

[19] Praxisgemeinschaft Frauenarzte Bahnhofspl, Hildesheim, Germany

[20] Helios Klinikum Berlin Buch, Genecol Oncol Ctr, Breast Canc Ctr, Clin Gynecol & Obstet, Berlin, Germany

[21] Onkol Aschaffenburg, Aschaffenburg, Germany

[22] Univ Hosp Wurzburg, Dept Gynecol & Obstet, Wurzburg, Germany

[23] Ludwig Maximilians Univ Munchen, LMU Univ Hosp, Dept Gynecol & Obstet, Breast Ctr, Munich, Germany

[24] Ludwig Maximilians Univ Munchen, LMU Univ Hosp, CCC Munich, Munich, Germany

[25] Agaples Markus Krankenhaus, Dept Gynecol & Gynecol Oncol, Frankfurt, Germany

[26] Univ Klinikum Leipzig, Klin & Poliklin Gynakol, Leipzig, Germany

来源：

GEBURTSHILFE UND FRAUENHEILKUNDE | 2021年 / 81卷 / 05期

关键词：

advanced breast cancer; biomarkers; therapy; prognosis; CIRCULATING TUMOR-CELLS; AGO RECOMMENDATIONS; DOUBLE-BLIND; SURVIVAL; PACLITAXEL; RIBOCICLIB; DIAGNOSIS; INDEX;

D O I：

10.1055/a-1464-1221

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

This review summarises and discusses significant aspects of recently published studies on patient treatment in advanced breast cancer and on biomarkers in breast cancer. In recent years, a large number of drugs for all molecular subtypes have been developed up to phase III trials. With regard to immune checkpoint inhibitors in metastasised breast cancer, the recent discussion has centred on the best candidate for combined chemotherapy. The oral taxanes could become a new type of oral chemotherapies. There is a growing body of data on biomarkers for the use of CDK4/6 inhibitors, which could also signify further development for other molecular subtypes. New substances have been developed for metastatic HER2+ breast cancer that still result in good remission even after massive prior treatment and/or cerebral metastasis. Similarly, knowledge is growing about targeted therapies with antibody-drug conjugates (ADC) against Trop-2, which could bolster our therapeutic armoury in triple-negative breast cancer (TNBC). In addition, the clinical focus is on understanding how to maintain fertility after breast cancer treatment. Here, pooled analyses provide new insights.

引用

页码：539 / 548

页数：10

共 39 条

[1] [Anonymous], 2013, J CLIN ONCOL, V31, P5, DOI [10.1200/jco.2013.31.18_suppl.5, 10.1200/jco.2013.31.18suppl.5, 10.1200/JCO.2013.31.18_SUPPL.5, DOI 10.1200/JCO.2013.31.18_SUPPL.5]
[2] ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
Bardia, A.
Tolaney, S. M.
Loirat, D.
Punie, K.
Oliveira, M.
Rugo, H. S.
Brufsky, A.
Kalinsky, K.
Cortes, J.
O'Shaughnessy, J.
Dieras, V. C.
Carey, L. A.
Gianni, L.
Piccart, M.
Loibl, S.
Goldenberg, D.
Hong, Q.
Olivo, M. S.
Itri, L. M.
Hurvitz, S. A.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S1149 - S1150
[3] Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
Bardia, A.
Mayer, I. A.
Vahdat, L. T.
Tolaney, S. M.
Isakoff, S. J.
Diamond, J. R.
O'Shaughnessy, J.
Moroose, R. L.
Santin, A. D.
Abramson, V. G.
Shah, N. C.
Rugo, H. S.
Goldenberg, D. M.
Sweidan, A. M.
Iannone, R.
Washkowitz, S.
Sharkey, R. M.
Wegener, W. A.
Kalinsky, K.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (08) : 741 - 751
[4] Barrios, 2020, SAN ANT BREAST CANC
[5] Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR plus breast cancer treated in the adjuvant tamoxifen-To offer more? (aTTom) trial.
Bartlett, John
Sgroi, Dennis
Treuner, Kai
Zhang, Yi
Piper, Tammy
Salunga, Ranelle C.
Ahmed, Ikhlaaq
Basnet, Kristen M.
Brachtel, Elena
Pirrie, Sarah
Schnabel, Catherine A.
Rea, Daniel William
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[6] Blondeaux E., 2020, SAN ANT BREAST CANC
[7] Circulating tumor cells in metastatic breast cancer - Toward individualized treatment?
Braun, S
Marth, C
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) : 824 - 826
[8] Cortes J, 2020, J CLIN ONCOL, V38
[9] Circulating tumor cells, disease progression, and survival in metastatic breast cancer
Cristofanilli, M
Budd, GT
Ellis, MJ
Stopeck, A
Matera, J
Miller, MC
Reuben, JM
Doyle, GV
Allard, WJ
Terstappen, LWMM
Hayes, DF
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) : 781 - 791
[10] Dent R., 2020, SAN ANT BREAST CANC

← 1 2 3 4 →